D. Medical Issued U.S. Patent No. 8050729
28 Novembro 2011 - 11:00AM
D. Medical Industries Ltd. (Nasdaq:DMED) (TASE:DMED) ("D. Medical"
or the "Company"), a medical device company engaged through its
subsidiaries in the research, development, manufacture and sale of
innovative products for diabetes treatment and drug delivery,
announced today that it has been granted U.S. Patent No. 8050729,
entitled "Devices For Continuous Measurement of Glucose in Body
Fluid."
This patent protects innovative technology that allows for the
combination of a minimally invasive Continuous Glucose Monitor and
an insulin pump on the same "patch." Amongst other features,
the technology enables the use of a single access point to both
accurately test for blood glucose levels and deliver insulin.
Hezkiah Tsoory, D. Medical's Chief Operating Officer, commented,
"The ability to accurately monitor glucose levels and deliver
insulin via a single device employing a common insertion point
represents a major breakthrough in the delivery of a safe,
convenient and minimally invasive experience for insulin pump
users. As we continue to develop our product pipeline for
commercialization, it is important that the innovations that will
define these future products are well protected. This U.S. patent
issuance serves again to strengthen D. Medical's already formidable
intellectual property estate."
About D. Medical
D. Medical is a medical device company engaged through its
subsidiaries in the research, development, manufacture and sale of
innovative products for diabetes treatment and drug delivery. D.
Medical has developed durable and semi-disposable insulin pumps,
which continuously infuse insulin into a patient's body, using its
proprietary spring-based delivery technology. D. Medical
believes that its spring-based delivery mechanism is cost-effective
compared to the motor and gear train mechanisms that drive
competitive insulin pumps and also allows it to incorporate certain
advantageous functions and design features in its insulin
pumps. D. Medical has also developed an infusion set for
insulin pumps and is focusing its research and development efforts
on the development of next generation insulin pumps and a device
that will combine a continuous glucose monitoring system and an
insulin pump on the same patch. For more information, please
visit http://www.dmedicalindustries.com (corporate) and
http://www.springnow.com (healthcare professionals, patients and
care givers).
Forward-Looking Statements
This press release contains forward-looking statements (as
defined by the Israeli Securities Law, 1968, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended) that involve risks and
uncertainties. These statements include, forecasts, goals,
uncertainties and assumptions and relate, inter alia, to D.
Medical's future expectations in connection with its level of sales
and cost of sales, manufacturing volumes, the cost-effectiveness of
its spring-based design, target markets, regulatory approvals and
timing of markets penetration. The forward-looking statements are
based on D. Medical's current expectations and beliefs which are
based on, among other things, its analysis of publicly available
information and market research reports. All forward-looking
statements are subject to certain risks, uncertainties and
assumptions that could cause actual results to differ materially
from those described in the forward-looking statements. Such risks
and uncertainties include, but are not limited to, the impact of
general economic conditions, competitive products, product demand,
product performance, the performance of D. Medical's contract
manufacturer and distributors, regulatory trends and approvals and
healthcare reform legislation. If one or more of these risks and/or
uncertainties materialize, or if the underlying assumptions prove
to be incorrect, D. Medical's actual results, performance or
achievements could differ materially from those expressed in, or
implied by, any such forward-looking statements or results which
are based upon such assumptions. No assurances can be given that
any of the events anticipated by the forward-looking statements
will transpire or occur, or if any of them will transpire or occur,
what impact it will have on D. Medical's results of operations or
financial condition. D. Medicals does not undertake to update any
forward-looking statements.
CONTACT: Company Contact:
Amir Loberman
Chief Financial Officer
D. Medical Industries LTD
T: +972-73-2507135
info@springnow.com
North American Investor Contact:
Stephen Kilmer
T: 212-618-6347
stephen@dmedicalindustries.com
Israeli Investor Relations:
Michal Efraty
T: +972-3-6950380
M: +972-52-3044404
michal@efraty.com
D. Medical Industries Ltd. - Ordinary Shares (MM) (NASDAQ:DMED)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
D. Medical Industries Ltd. - Ordinary Shares (MM) (NASDAQ:DMED)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024